<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-157082" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Necrolytic Acral Erythema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Guraya</surname>
            <given-names>Armaan</given-names>
          </name>
          <aff>Midwestern University Chicago College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kamel</surname>
            <given-names>Joseph</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Armaan Guraya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joseph Kamel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-157082.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Necrolytic acral erythema is a rare dermatological condition predominantly associated with chronic hepatitis C virus (HCV) infection. First described in 1996, necrolytic acral erythema is characterized by painful, erythematous, eroded, and occasionally bullous plaques primarily affecting the acral areas, such as the hands and feet.<xref ref-type="bibr" rid="article-157082.r1">[1]</xref> Although not fully understood, the pathogenesis of this condition is believed to involve complex interactions between nutritional deficiencies, particularly zinc, and chronic liver disease. Necrolytic acral erythema is a crucial cutaneous marker for HCV infection, often presenting in patients with long-standing, untreated, or poorly managed HCV.&#x000a0;The lesions are typically well-demarcated, erythematous, eroded plaques with superficial necrosis and crusting.<xref ref-type="bibr" rid="article-157082.r2">[2]</xref>&#x000a0;Necrolytic acral erythema typically follows a chronic course with recurrent episodes of exacerbation and remission.</p>
        <p>Diagnosis involves a comprehensive evaluation to uncover underlying causes and metabolic abnormalities, emphasizing testing for HCV. Histological analysis may be required to differentiate necrolytic acral erythema from other similar skin conditions.&#x000a0;Without appropriate management, the condition can persist and lead to significant discomfort and secondary infections due to impaired skin barrier.<xref ref-type="bibr" rid="article-157082.r3">[3]</xref>&#x000a0;Treatment focuses on addressing the HCV infection and the skin lesions, with oral zinc therapy showing significant effectiveness. Despite its apparent association with HCV, necrolytic acral erythema remains poorly understood and underreported, making its prevalence and incidence challenging to determine.</p>
      </sec>
      <sec id="article-157082.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Necrolytic acral erythema is primarily associated with HCV infection, which is central to its pathogenesis. The exact mechanism by which HCV leads to necrolytic acral erythema is not fully elucidated but involves several key factors.&#x000a0;The virus may induce skin changes through direct viral effects, immune-mediated mechanisms, or metabolic disturbances related to liver dysfunction.<xref ref-type="bibr" rid="article-157082.r4">[4]</xref></p>
      </sec>
      <sec id="article-157082.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Necrolytic acral erythema was initially reported among patients in areas with highly prevalent and untreated HCV infection, such as Egypt. Subsequent studies have reported cases from various regions worldwide, including the Middle East, Asia, Europe, and North America. However, the prevalence and incidence of necrolytic acral erythema remain poorly defined due to its rarity and underreporting in clinical practice.<xref ref-type="bibr" rid="article-157082.r5">[5]</xref>&#x000a0;Although initially considered a rare dermatosis, its association with chronic HCV infection has led to increased recognition in regions with a high prevalence of HCV.&#x000a0;Necrolytic acral erythema predominantly affects adults, with the majority of reported cases occurring in individuals between the ages of 40 and 60, and does not appear to have a gender predilection.<xref ref-type="bibr" rid="article-157082.r6">[6]</xref> Chronic HCV infection is considered the primary associated factor in the pathogenesis of necrolytic acral erythema.&#x000a0;Infection is common in patients with necrolytic acral erythema; however, viral loads are not necessarily elevated.<xref ref-type="bibr" rid="article-157082.r7">[7]</xref></p>
      </sec>
      <sec id="article-157082.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Zinc deficiency is a well-recognized factor in the development of necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r7">[7]</xref> Zinc is an essential cofactor in numerous enzymatic processes, including skin integrity and repair.<xref ref-type="bibr" rid="article-157082.r8">[8]</xref>&#x000a0;Experts have also hypothesized that HCV infection exacerbates zinc deficiency by altering zinc metabolism or through the systemic inflammatory response it provokes. In addition, the infection can lead to liver dysfunction, affecting metabolic processes and nutritional status.&#x000a0;</p>
        <p>Acrodermatitis enteropathica, a condition caused by zinc deficiency, provides a pertinent example of this pathophysiology. This autosomal recessive disorder is characterized by mutations in <italic toggle="yes">SLC39A4</italic>, which encodes a zinc transporter protein essential for zinc uptake in the intestine. The resulting impaired zinc absorption manifests as acral and periorificial dermatitis, alopecia, and diarrhea.&#x000a0;Both necrolytic acral erythema and acrodermatitis enteropathica highlight zinc's critical role in maintaining skin health and the systemic consequences of its deficiency. Understanding the pathophysiology of zinc deficiency in necrolytic acral erythema, including its impact on enzymatic processes and skin integrity, underscores the importance of addressing zinc levels in affected patients.<xref ref-type="bibr" rid="article-157082.r9">[9]</xref>&#x000a0;In addition, malabsorption of essential nutrients, including amino acids and vitamins, can contribute to skin manifestations. The resultant hypoaminoacidemia may impair protein synthesis and skin barrier function, exacerbating the symptoms of necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r10">[10]</xref></p>
      </sec>
      <sec id="article-157082.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histology of necrolytic acral erythema depends on the disease's location and stage at the time of biopsy. In the early stages, the outer layer of the epidermis exhibits necrosis, leading to blister formation as the epidermis detaches from the underlying tissue. Histologically, the epidermis shows thickening (acanthosis) and intercellular edema (spongiosis), accompanied by superficial dermal inflammatory infiltrate resembling nummular dermatitis. The accumulation of necrotic keratinocytes can lead to the formation of clefts in the upper epidermis (see <bold>Image</bold>.&#x000a0;Necrolytic Acral Erythema Histopathology). In addition, areas of dyskeratosis (abnormal keratinization) and epidermal pallor help differentiate necrolytic acral erythema from psoriasis. The characteristic necrosis of keratinocytes and vacuolar degeneration of some basal cells are critical diagnostic features of necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r11">[11]</xref></p>
      </sec>
      <sec id="article-157082.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with necrolytic acral erythema may be unaware of their HCV status. Moreover, given the different stages and durations of necrolytic acral erythema, history may be variable, with lesions presenting intermittently.<xref ref-type="bibr" rid="article-157082.r6">[6]</xref>&#x000a0;Necrolytic acral erythema is characterized by painful, erythematous, eroded, and occasionally bullous plaques primarily affecting the acral areas, such as the hands and feet.<xref ref-type="bibr" rid="article-157082.r1">[1]</xref>&#x000a0;</p>
        <p>Physical examination findings may show lesions in 3 distinct stages&#x02014;initial, well-developed, and late. The initial stage presents with lesions that begin as small, erythematous macules or plaques that gradually enlarge and develop central necrosis and crusting.&#x000a0;In the well-developed&#x000a0;stages, the lesions merge to form distinct, thick, dark plaques with attached scales. As the condition progresses to the late stage, the lesions become more circumscribed, thinner, and hyperpigmented.<xref ref-type="bibr" rid="article-157082.r1">[1]</xref></p>
      </sec>
      <sec id="article-157082.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of necrolytic acral erythema involves a thorough investigation to identify underlying causes and metabolic disturbances. Early recognition of necrolytic acral erythema is crucial for diagnosing and treating any underlying conditions, particularly HCV infection.&#x000a0;In more than 75% of necrolytic acral erythema cases, HCV is diagnosed for the first time, highlighting the importance of HCV serology in all patients with necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r1">[1]</xref></p>
        <p>Although no specific diagnostic laboratory tests exist for necrolytic acral erythema, a comprehensive biochemical evaluation is essential. Serum zinc levels are typically normal, though isolated reports indicate occasional low levels.<xref ref-type="bibr" rid="article-157082.r12">[12]</xref><xref ref-type="bibr" rid="article-157082.r13">[13]</xref>&#x000a0;In addition, measuring amino acid and albumin levels is important, as these may be abnormal in some patients. Normal glucagon levels can help to differentiate necrolytic acral erythema from necrolytic migratory erythema. Liver function tests, including transaminase levels and total serum bilirubin, are crucial, particularly for HCV patients. Abnormal liver function tests and ultrasonography findings are common, reported in 84.3% and 76.9% of cases, respectively.<xref ref-type="bibr" rid="article-157082.r6">[6]</xref> Furthermore, investigations should be conducted to rule out other differential diagnoses based on the clinical presentation of necrolytic acral erythema. This diagnostic approach results in more accurate identification and appropriate management of the condition.</p>
      </sec>
      <sec id="article-157082.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of necrolytic acral erythema focuses on treating both the underlying cause and the skin manifestations. In patients with HCV infection, antiviral treatments such as ribavirin and interferon-alpha have been shown to improve the condition, even if the viral load remains high. Interferon-alpha monotherapy has also been effective. Oral zinc therapy is recognized as the most effective treatment for necrolytic acral erythema, even in patients without a deficiency. Interestingly, zinc therapy has also been noted to enhance the efficacy of interferon treatment in HCV patients with necrolytic acral erythema.&#x000a0;A 220 mg oral zinc regimen taken twice daily for up to 8 weeks has been shown to clear skin findings.<xref ref-type="bibr" rid="article-157082.r14">[14]</xref>&#x000a0;Other treatments have been explored with varied results. Mid- to high-potency topical and systemic corticosteroids and topical tacrolimus have been tried with mixed results.<xref ref-type="bibr" rid="article-157082.r15">[15]</xref>&#x000a0;Phototherapy methods, including psoralen plus ultraviolet A therapy and narrowband ultraviolet B therapy, have also been tested but have not&#x000a0;shown&#x000a0;benefit.<xref ref-type="bibr" rid="article-157082.r16">[16]</xref></p>
      </sec>
      <sec id="article-157082.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Necrolytic acral erythema can be misdiagnosed as several other dermatological conditions with similar clinical features, including erythema, scaling, and psoriasiform plaques. Accurate differentiation is crucial for appropriate diagnosis and treatment. Conditions presenting with acral erythemas include acrodermatitis enteropathica, the dermatitis of niacin deficiency, and deficiencies such as biotin and fatty acid. These conditions typically have a distinctive acral distribution and lack systemic symptoms, which helps distinguish them from necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r17">[17]</xref><xref ref-type="bibr" rid="article-157082.r18">[18]</xref>&#x000a0;</p>
        <p>Psoriasis often presents with well-demarcated, erythematous plaques covered with silvery scales commonly located on the elbows, knees, scalp, and lower back. Necrolytic acral erythema can be differentiated from psoriasis by its dark and verrucous scales and the absence of central clearing in the lesions. Histopathological examination may sometimes be required to confirm the diagnosis and exclude psoriasis.<xref ref-type="bibr" rid="article-157082.r19">[19]</xref>&#x000a0;Lichen simplex chronicus is another skin disorder characterized by thickened, scaly patches resulting from chronic rubbing or scratching. The lesions are typically well-defined, lichenified plaques that are intensely pruritic. Unlike necrolytic acral erythema, lichen simplex chronicus lacks necrotic features and systemic associations with HCV. However, late stages of necrolytic acral erythema may appear lichenified. Differentiation is based on a clinical history of chronic itching and physical examination, though a biopsy may be used to confirm the diagnosis if necessary.<xref ref-type="bibr" rid="article-157082.r20">[20]</xref></p>
        <p>Erythrokeratoderma manifests as hyperkeratotic, erythematous plaques, often in a geographic or linear pattern, and typically appears in infancy or childhood. Unlike necrolytic acral erythema, erythrokeratoderma typically shows symmetrical distribution and has a genetic basis.<xref ref-type="bibr" rid="article-157082.r21">[21]</xref>&#x000a0;Nummular eczema is characterized by coin-shaped, erythematous, and scaly plaques, often associated with itching and discomfort. The absence of well-defined lesions and verrucous scales observed in necrolytic acral erythema helps differentiate these conditions.<xref ref-type="bibr" rid="article-157082.r22">[22]</xref>&#x000a0;In addition, dermatophytosis presents with erythematous plaques with central clearing and peripheral scaling, typically caused by fungal infections. The absence of central clearing and the distinct histopathological features of necrolytic acral erythema assist in distinguishing it from dermatophytosis.<xref ref-type="bibr" rid="article-157082.r17">[17]</xref><xref ref-type="bibr" rid="article-157082.r10">[10]</xref><xref ref-type="bibr" rid="article-157082.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-157082.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of necrolytic acral erythema varies and largely depends on recognizing the underlying cause, the effectiveness of the treatment administered, and&#x000a0;a timely diagnosis. As necrolytic acral erythema is commonly associated with HCV infection, successful management of the underlying HCV can significantly improve skin lesions and overall outcomes.<xref ref-type="bibr" rid="article-157082.r23">[23]</xref>&#x000a0;Nonetheless, some reports indicate that necrolytic acral erythema lesions can reappear after stopping interferon treatment, and instances of necrolytic acral erythema recurrence might align with the return of liver disease symptoms and the recovery of HCV viral load. Moreover, mixed findings regarding the association between hepatic disease and skin burden have been reported.<xref ref-type="bibr" rid="article-157082.r24">[24]</xref> The delay in diagnosing necrolytic acral erythema can negatively impact the prognosis due to its wide range of possible diagnoses and rarity.<xref ref-type="bibr" rid="article-157082.r24">[24]</xref></p>
      </sec>
      <sec id="article-157082.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The complications of necrolytic acral erythema primarily arise from its persistent and recurrent lesions, which can be chronic, particularly if the underlying HCV infection is not adequately controlled.<xref ref-type="bibr" rid="article-157082.r6">[6]</xref> These lesions can be painful, causing significant discomfort and impacting the patient's quality of life. Moreover, they are prone to secondary infections, especially if the skin barrier is compromised due to ulceration or scratching.</p>
        <p>Chronic or recurrent necrolytic acral erythema lesions often lead to scarring and postinflammatory hyperpigmentation, which can be cosmetically concerning for patients. As necrolytic acral erythema typically affects the hands and feet, severe cases can impair the patient's mobility and ambulation, further diminishing their quality of life.<xref ref-type="bibr" rid="article-157082.r25">[25]</xref>&#x000a0;</p>
        <p>Necrolytic acral erythema is closely linked to chronic HCV, a condition that can lead to severe complications, including cirrhosis, liver failure, and hepatocellular carcinoma, if not adequately managed. This association underscores the importance of addressing the underlying infection in treating necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r26">[26]</xref> However, treatment challenges arise when HCV therapy is discontinued or proves ineffective, as this can lead to relapses of necrolytic acral erythema, complicating overall disease management.<xref ref-type="bibr" rid="article-157082.r10">[10]</xref></p>
      </sec>
      <sec id="article-157082.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Effective deterrence strategies include routine screening and early treatment of HCV to reduce the risk of developing necrolytic acral erythema.<xref ref-type="bibr" rid="article-157082.r10">[10]</xref>&#x000a0;Patient education should focus on raising awareness about the relationship between HCV and necrolytic acral erythema, emphasizing the importance of maintaining liver health and adhering to antiviral therapies.<xref ref-type="bibr" rid="article-157082.r27">[27]</xref> Patients should be informed about the characteristic symptoms of necrolytic acral erythema, such as erythematous and scaly lesions on the extremities, to promote early detection and prompt medical consultation. Educating patients on skin care practices and the importance of follow-up visits can help manage symptoms and prevent complications. Comprehensive education empowers patients to participate actively in their care, improving outcomes and quality of life.</p>
      </sec>
      <sec id="article-157082.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective management of necrolytic acral erythema requires a collaborative approach involving various healthcare professionals. Dermatologists and hepatologists are crucial in diagnosing necrolytic acral erythema and managing the associated HCV infection. At the same time, advanced practitioners and nurses play essential roles in educating patients, monitoring treatment adherence, and providing comprehensive skin care. Pharmacists ensure the safe and effective use of medications, such as antiviral therapies and zinc supplements, critical for treating necrolytic acral erythema. Interprofessional communication is crucial for successful management. Regular team meetings and coordination among team members ensure everyone is informed about the patient's status, treatment progress, and any complications, allowing for timely treatment adjustments.</p>
        <p>Care coordination is also crucial in enhancing patient outcomes, including scheduling regular follow-ups to monitor the effectiveness of HCV treatment and the progression of skin lesions and coordinating necessary laboratory tests such as liver function tests and serum zinc levels. Advanced practitioners and nurses often act as case managers, ensuring patients adhere to their treatment regimens and attend scheduled appointments. A patient-centered approach is essential in managing necrolytic acral erythema. Engaging patients in their care by educating them about the connection between HCV and necrolytic acral erythema, stressing the importance of adhering to antiviral therapy and zinc supplementation, and teaching effective skin care practices can significantly improve outcomes. Adopting evidence-based strategies is critical for optimizing necrolytic acral erythema management. Antiviral treatments such as ribavirin and interferon-alpha have shown improvement in necrolytic acral erythema lesions, whereas zinc supplementation has also been effective, even in the absence of zinc deficiency. The healthcare team can significantly enhance patient outcomes and overall team performance in managing necrolytic acral erythema by focusing on interprofessional collaboration, effective communication, coordinated care, patient-centered approaches, and evidence-based strategies. Regularly updating care protocols based on the latest research ensures the team remains at the forefront of effective necrolytic acral erythema management, ultimately reducing morbidity and improving the quality of life for patients.</p>
      </sec>
      <sec id="article-157082.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=157082&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=157082">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/necrolytic-acral-erythema/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=157082">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/157082/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=157082">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-157082.s15">
        <fig id="article-157082.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Necrolytic Acral Erythema Histopathology. Histologically, the epidermis shows thickening (acanthosis) and intercellular edema (spongiosis), accompanied by superficial dermal inflammatory infiltrate resembling nummular dermatitis. The accumulation of necrotic keratinocytes can lead to the formation of clefts in the upper epidermis. Contributed by N Sathe, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="necrolytic__acral__erythema" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-157082.s16">
        <title>References</title>
        <ref id="article-157082.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdallah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ghozzi</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Monib</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hafez</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hiatt</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Smoller</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema: a cutaneous sign of hepatitis C virus infection.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>247</fpage>
            <page-range>247-51</page-range>
            <pub-id pub-id-type="pmid">16021118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arbabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirkland</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Extrahepatic Manifestations of Chronic Hepatitis C Virus (HCV) Infection.</article-title>
            <source>Cureus</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>e57343</fpage>
            <pub-id pub-id-type="pmid">38562366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yost</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema.</article-title>
            <source>Dermatol Online J</source>
            <year>2013</year>
            <month>Dec</month>
            <day>16</day>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>20709</fpage>
            <pub-id pub-id-type="pmid">24365000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srisuwanwattana</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vachiramon</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic Acral Erythema in Seronegative Hepatitis C.</article-title>
            <source>Case Rep Dermatol</source>
            <year>2017</year>
            <season>Jan-Apr</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-73</page-range>
            <pub-id pub-id-type="pmid">28611625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Ghandour</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Sakr</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>El-Sebai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>El-Gammal</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>El-Sayed</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema in Egyptian patients with hepatitis C virus infection.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>1200</fpage>
            <page-range>1200-6</page-range>
            <pub-id pub-id-type="pmid">16824076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Darouti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mashaly</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>El-Nabarawy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eissa</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Abdel-Halim</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Fawzi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>El-Eishi</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Tawfik</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Zaki</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Zidan</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Fawzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdelaziz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fawzi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>OG</given-names>
              </name>
            </person-group>
            <article-title>Leukocytoclastic vasculitis and necrolytic acral erythema in patients with hepatitis C infection: do viral load and viral genotype play a role?</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-65</page-range>
            <pub-id pub-id-type="pmid">20462666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inamadar</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Shivanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ankad</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic Acral Erythema: Current Insights.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>275</fpage>
            <page-range>275-281</page-range>
            <pub-id pub-id-type="pmid">32308461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiGuilio</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Rybakovsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abdavies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chamoun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flounders</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Shepley-McTaggart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harty</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Mullin</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Micronutrient Improvement of Epithelial Barrier Function in Various Disease States: A Case for Adjuvant Therapy.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Mar</month>
            <day>10</day>
            <volume>23</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35328419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jagadeesan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaliyadan</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <chapter-title>Acrodermatitis Enteropathica</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">28722865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geria</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Holcomb</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Scheinfeld</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema: a review of the literature.</article-title>
            <source>Cutis</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>83</volume>
            <issue>6</issue>
            <fpage>309</fpage>
            <page-range>309-14</page-range>
            <pub-id pub-id-type="pmid">19681342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdallah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ghozzi</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Monib</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hafez</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hiatt</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Smoller</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Histological study of necrolytic acral erythema.</article-title>
            <source>J Ark Med Soc</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>100</volume>
            <issue>10</issue>
            <fpage>354</fpage>
            <page-range>354-5</page-range>
            <pub-id pub-id-type="pmid">15080276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jakubovic</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Zipursky</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McCall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jakubovic</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Zinc deficiency presenting with necrolytic acral erythema and coma.</article-title>
            <source>Am J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>128</volume>
            <issue>8</issue>
            <fpage>e3</fpage>
            <page-range>e3-4</page-range>
            <pub-id pub-id-type="pmid">25863150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moneib</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Darwish</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of zinc level in skin of patients with necrolytic acral erythema.</article-title>
            <source>Br J Dermatol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>163</volume>
            <issue>3</issue>
            <fpage>476</fpage>
            <page-range>476-80</page-range>
            <pub-id pub-id-type="pmid">20426777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdallah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hull</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc.</article-title>
            <source>Arch Dermatol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>141</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-7</page-range>
            <pub-id pub-id-type="pmid">15655150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manzur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema: successful treatment with topical tacrolimus ointment.</article-title>
            <source>Int J Dermatol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1073</fpage>
            <page-range>1073-5</page-range>
            <pub-id pub-id-type="pmid">18986360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raphael</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Dorey-Stein</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Lott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amorosa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lo Re</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kovarik</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>962</fpage>
            <page-range>962-8</page-range>
            <pub-id pub-id-type="pmid">22325461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nofal</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nofal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Attwa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>El-Assar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Assaf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema: a variant of necrolytic migratory erythema or a distinct entity?</article-title>
            <source>Int J Dermatol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>916</fpage>
            <page-range>916-21</page-range>
            <pub-id pub-id-type="pmid">16336523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santaliz-Ruiz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Marrero-P&#x000e9;rez</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Pont</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nev&#x000e1;rez-Pomales</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Acrodermatitis dysmetabolica with concomitant acquired acrodermatitis enteropathica in a patient with maple syrup urine disease.</article-title>
            <source>JAAD Case Rep</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>45</volume>
            <fpage>7</fpage>
            <page-range>7-10</page-range>
            <pub-id pub-id-type="pmid">38333677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boehncke</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>Sep</month>
            <day>05</day>
            <volume>386</volume>
            <issue>9997</issue>
            <fpage>983</fpage>
            <page-range>983-94</page-range>
            <pub-id pub-id-type="pmid">26025581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ju</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vander Does</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohsin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yosipovitch</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lichen Simplex Chronicus Itch: An Update.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2022</year>
            <month>Oct</month>
            <day>19</day>
            <volume>102</volume>
            <fpage>adv00796</fpage>
            <pub-id pub-id-type="pmid">36250769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croitoru</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lara-Corrales</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kannu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>ELOVL4 with erythrokeratoderma: A pediatric case and emerging genodermatosis.</article-title>
            <source>Am J Med Genet A</source>
            <year>2021</year>
            <month>May</month>
            <volume>185</volume>
            <issue>5</issue>
            <fpage>1619</fpage>
            <page-range>1619-1623</page-range>
            <pub-id pub-id-type="pmid">33655653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000fc;ppop</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D&#x000e4;hnhardt-Pfeiffer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>F&#x000f6;lster-Holst</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Characterization of Classical Flexural and Nummular Forms of Atopic Dermatitis in Childhood with Regard to Anamnestic, Clinical and Epidermal Barrier Aspects.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>08</day>
            <volume>102</volume>
            <fpage>adv00664</fpage>
            <pub-id pub-id-type="pmid">34935994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>el Darouti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abu el Ela</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema: a cutaneous marker of viral hepatitis C.</article-title>
            <source>Int J Dermatol</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>252</fpage>
            <page-range>252-6</page-range>
            <pub-id pub-id-type="pmid">8786182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bentley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Andea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Lack of classic histology should not prevent diagnosis of necrolytic acral erythema.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>504</fpage>
            <page-range>504-7</page-range>
            <pub-id pub-id-type="pmid">18992966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oikonomou</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Sarpel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abrams-Downey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mubasher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dieterich</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Necrolytic acral erythema in a human immunodeficiency virus/hepatitis C virus coinfected patient: A case report.</article-title>
            <source>World J Hepatol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>27</day>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <page-range>226-233</page-range>
            <pub-id pub-id-type="pmid">30820272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooq</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oyibo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Divall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Choudhry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review.</article-title>
            <source>World J Gastrointest Oncol</source>
            <year>2024</year>
            <month>Apr</month>
            <day>15</day>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>1596</fpage>
            <page-range>1596-1612</page-range>
            <pub-id pub-id-type="pmid">38660636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157082.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiznia</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Laird</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1260</fpage>
            <page-range>1260-1270</page-range>
            <pub-id pub-id-type="pmid">28252812</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
